The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Integrated Assessment of the Clinical Performance of GalNAc 3 -Conjugated 2′- O -Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience
Open accessAbstract
Advances in medicinal chemistry have produced new chemical classes of antisense oligonucleotides (ASOs) with enhanced therapeutic properties. Conjugation of the triantennary N -acetylgalactosamine (GalNAc 3 ) moiety to the extensively characterized phosphorothioate (PS)-modified 2′- O -methoxyethyl (2′MOE) ASO exemplifies such an advance. This structure-activity optimized moiety effects receptor-mediated uptake of the ASO prodrug through the asialoglycoprotein receptor 1 to support selective targeting of RNAs expressed by hepatocytes. In this study we report the integrated assessment of data available from randomized placebo-controlled dose-ranging studies of this chemical class of ASOs administered systemically to healthy human volunteers. First, we compare the pharmacokinetic and pharmacodynamic profiles of a subset of the GalNAc 3 -conjugated PS-modified 2′MOE ASOs to the parent PS-modified 2′MOE ASOs for which plasma analytes are available. We then evaluate the safety profile of the full set of GalNAc 3 -conjugated PS-modified 2′MOE ASO conjugates by the incidence of signals in standardized laboratory tests and by the mean laboratory test results as a function of dose level over time. With hepatocyte targeted delivery, the ED 50 for the GalNAc 3 -conjugated PS-modified 2′MOE ASO subset ranges from 4 to 10 mg/week, up to 30-fold more potent than the parent PS-modified 2′MOE ASO. No GalNAc 3 -conjugated PS-modified 2′MOE ASO class effects were identified from the assessment of the integrated laboratory test data across all doses tested with either single or multidose regimens. The increase in potency supports an increase in the safety margin for this new chemical class of ASOs now under broad investigation in the clinic. Although the total exposure is limited in the initial phase 1 trials, ongoing and future investigations in patient populations will support evaluation of the effects of long-term exposure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“With regard to safety, there were no confirmed instances of reduced renal function or platelet count with vupanorsen, 2 issues that have been observed with some first-generation antisense oligonucleotides.16,17”
From Effect of Vupanorsen on Non–High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70 (2022) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
Finkel, R. S., Mercuri, E., Darras, B. T., Connolly, A. M., Kuntz, N. L., Kirschner, J., Chiriboga, C. A., Saito, K., Servais, L., Tizzano, E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702752 · Cited by 2,337
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Benson, M. D., Waddington‐Cruz, M., Berk, J. L., Polydefkis, M. J., Dyck, P. J. B., Wang, A. K., Planté‐Bordeneuve, V., Barroso, F. A., Merlini, G., Obici, L. P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716793 · Cited by 1,483
Self-citationNusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
Mercuri, E., Darras, B. T., Chiriboga, C. A., Day, J. W., Campbell, C., Connolly, A. M., Iannaccone, S. T., Kirschner, J., Kuntz, N. L., Saito, K., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1710504 · Cited by 1,433
Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides
Geary, R. S., Norris, D. A., Yu, R. Z., & Bennett, C. F. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.008 · Cited by 866
Self-citationCrooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841
Self-citationViney, N. J., van Capelleveen, J. C., Geary, R. S., Xia, S., Tami, J. A., Yu, R. Z., Marcovina, S. M., Hughes, S. G., Graham, M. J., Crooke, R. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31009-1 · Cited by 754
Self-citationPrakash, T. P., Graham, M., Yu, J., Carty, R., Low, A., Chappell, A., Schmidt, K., Zhao, C., Aghajan, M., Murray, H., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku531 · Cited by 588
Cellular uptake and trafficking of antisense oligonucleotides
Crooke, S. T., Wang, S., Vickers, T. A., Shen, W., & Liang, X.-H. (2017) · Nature Biotechnology · doi:10.1038/nbt.3779 · Cited by 582
Self-citationCardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
Graham, M. J., Lee, R. G., Brandt, T. A., Tai, L.-J., Fu, W., Peralta, R., Yu, R., Hurh, E., Paz, E., McEvoy, B. W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701329 · Cited by 573
Self-citationPharmacology of Antisense Drugs
Bennett, C. F., Baker, B. F., Pham, N. C., Swayze, E. E., & Geary, R. S. (2016) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104846 · Cited by 445
Self-citation
Flagged first, then by citations
Research works printed but not linked: 10
- Crooke ST, , Vickers T, , Lima W, and Wu H. (2008). Mechanisms of antisense drug action, an introduction. In: Antisense Drug Technology: Principles, Strategies, and Applications, 2nd edn. Crooke ST, ed. CRC Press, Boca Raton, FL, pp 3–46.
- Swayze EE, and Bhat B. (2008). The medicinal chemistry of oligonucleotides. In: Antisense Drug Technology: Principles, Strategies, and Applications, 2nd edn. Crooke ST, ed. CRC Press, Boca Raton, pp 143–182.
- Levin AA, , Yu RZ, and Geary RS. (2008). Basic principles of the pharmacokinetics of antisense oligonucleotide drugs. In: Antisense Drug Technology: Principles, Strategies, and Applications, 2nd edn. Crooke ST, ed. CRC Press, Boca Raton, FL, pp 183–215.
- Iversen PL. (2008). Morpholinos. In: Antisense Drug Technology: Principles, Strategies, and Applications. Crooke ST, ed. CRC Press, Boca Raton, pp 565–582.
- Manoharan M, and Rajeev KG. (2008). Utilizing chemistry to harness RNA interference pathways for therapeutics: Chemically modified siRNA and Anatgomirs. In: Antisense Drug Technology: Principles, Strategies, and Applications. Crooke ST, ed. CRC Press, Boca Raton, pp 437–464.
- Mercuri E, , Finkel R, , Kirschner J, , Chiriboga C, , Kuntz N, , Sun P, , Gheuens S, , Bennett C, , Schneider E, and Farwell W. (2017). Efficacy and safety of nusinersen in children with later-onset spinal muscular atrophy (SMA): end of study results from the phase 3 CHERISH study. Neuromuscul Disord, 27:S210. · DOI
- Lima W, , Wu H, and Crooke ST. (2008). The RNase H mechanism. In: Antisense Drug Technology: Principles, Strategies, and Applications, 2nd edn. Crooke ST, ed. CRC Press, Boca Raton, FL, pp 47–74.
- Geary RS, , Yu RZ, , Siwkowski A, and Levin AA. (2008). Pharmacokinetic/pharmacodynamic properties of phosphorothioate 2′-O-(2-methoxyethyl)-modified antisense oligonucleotides in animals and man. In: Antisense Drug Technology: Principles, Strategies, and Applications, 2nd edn. Crooke ST, ed. CRC Press, Boca Raton, FL, pp 305–326.
- Bennett CF. (2008). Pharmacological properties of 2′-methoxyethyl-modified oligonucleotides. In: Antisense Drug Technology: Principles, Strategies, and Applications, 2nd edn. Crooke ST, ed. CRC Press, Boca Raton, FL, pp 273–303.
- Ämmälä C, , Ahlstedt I, , Andersson E-M, , Andersson P, , Cavallin E, , Drury W, , Hung G, , Jansson-Löfmark R, , Johansson C, et al. (2017). The GLP1 receptor as a homing beacon for targeted delivery to pancreatic ß-cells: quantitating tissue selective productive uptake of antisense oligonucleotides. Diabetes, 66:A568.
Cited by
Sorted by citations
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
Tsimikas, S., Karwatowska-Prokopczuk, E., Gouni-Berthold, I., Tardif, J.-C., Baum, S. J., Steinhagen-Thiessen, E., Shapiro, M. D., Stroes, E. S., Moriarty, P. M., Nordestgaard, B. G., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1905239 · Cited by 1,094
Self-citationAntisense technology: an overview and prospectus
Crooke, S. T., Baker, B. F., Crooke, R. M., & Liang, X.-H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00162-z · Cited by 775
Self-citationRecent Progress in Aptamer Discoveries and Modifications for Therapeutic Applications
Ni, S., Zhuo, Z., Pan, Y., Yu, Y., Li, F., Liu, J., Wang, L., Wu, X., Li, D., Wan, Y., et al. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c05750 · Cited by 605
Delivery of oligonucleotides to the liver with GalNAc: From research to registered therapeutic drug.
Debacker, A. J., Voutila, J., Catley, M., Blakey, D., & Habib, N. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.015 · Cited by 424
Phosphorothioate modified oligonucleotide–protein interactions
Crooke, S. T., Vickers, T. A., & Liang, X.-H. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa299 · Cited by 372
Self-citationAntisense technology: A review
Crooke, S. T., Liang, X., Baker, B. F., & Crooke, R. M. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100416 · Cited by 350
Self-citationThe powerful world of antisense oligonucleotides: From bench to bedside
Quéméner, A. M., Bachelot, L., Forestier, A., Donnou‐Fournet, E., Gilot, D., & Galibert, M. (2020) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1594 · Cited by 284
Gaudet, D., Karwatowska-Prokopczuk, E., Baum, S. J., Hurh, E., Kingsbury, J., Bartlett, V. J., Figueroa, A. L., Piscitelli, P., Singleton, W., Witztum, J. L., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa689 · Cited by 279
Self-citationAlexander, V. J., Xia, S., Hurh, E., Hughes, S. G., O’Dea, L., Geary, R. S., Witztum, J. L., & Tsimikas, S. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz209 · Cited by 231
Self-citationTardif, J.-C., Karwatowska-Prokopczuk, E., Amour, E. S., Ballantyne, C. M., Shapiro, M. D., Moriarty, P. M., Baum, S. J., Hurh, E., Bartlett, V. J., Kingsbury, J., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab820 · Cited by 210
Self-citationBergmark, B. A., Marston, N. A., Bramson, C. R., Curto, M., Ramos, V., Jevne, A., Kuder, J. F., Park, J.-G., Murphy, S. A., Verma, S., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.059266 · Cited by 216
Recent Advances in Oligonucleotide Therapeutics in Oncology
Xiong, H., Veedu, R. N., & Diermeier, S. D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073295 · Cited by 194
Liu, M., Wang, Y., Zhang, Y.-B., Hu, D., Tang, L., Zhou, B., & Yang, L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02112-8 · Cited by 189
Self-citationLiver-Targeted Delivery of Oligonucleotides with N-Acetylgalactosamine Conjugation
Cui, H., Zhu, X., Li, S., Wang, P., & Fang, J. (2021) · ACS Omega · doi:10.1021/acsomega.1c01755 · Cited by 132
Crooke, S. T., Seth, P. P., Vickers, T. A., & Liang, X. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c04928 · Cited by 131
Self-citationAn oral antisense oligonucleotide for PCSK9 inhibition
Gennemark, P., Walter, K., Clemmensen, N., Rekić, D., Nilsson, C. A. M., Knöchel, J., Hölttä, M., Wernevik, L. C., Rosengren, B. E., Kakol‐Palm, D., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe9117 · Cited by 125
Self-citationLoomba, R. S., Morgan, E. S., Watts, L. M., Xia, S., Hannan, L. A., Geary, R. S., Baker, B. F., & Bhanot, S. (2020) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(20)30186-2 · Cited by 113
Self-citationAntisense drug discovery and development technology considered in a pharmacological context
Crooke, S. T., Liang, X., Crooke, R. M., Baker, B. F., & Geary, R. S. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114196 · Cited by 109
Self-citationØstergaard, M. E., Jackson, M., Low, A., Chappell, A. E., Lee, R. G., Peralta, R. Q., Yu, J., Kinberger, G. A., Dan, A., Carty, R., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz360 · Cited by 101
Viney, N. J., Guo, S., Tai, L.-J., Baker, B. F., Aghajan, M., Jung, S. W., Yu, R. Z., Booten, S. L., Murray, H., Machemer, T., et al. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13154 · Cited by 98
Self-citationWang, Y., Yu, R. Z., Henry, S. P., & Geary, R. S. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1621838 · Cited by 104
Self-citationAntisense Inhibition of Angiotensinogen With IONIS-AGT-LRx
Morgan, E. S., Tami, Y., Hu, K., Brambatti, M., Mullick, A. E., Geary, R. S., Bakris, G. L., & Tsimikas, S. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.04.004 · Cited by 97
Self-citationNucleic Acid Drugs—Current Status, Issues, and Expectations for Exosomes
Yamada, Y. (2021) · Cancers · doi:10.3390/cancers13195002 · Cited by 92
Efficacy and Safety of Donidalorsen for Hereditary Angioedema
Riedl, M. A., Tachdjian, R., Lumry, W. R., Craig, T., Karakaya, G., Gelincik, A. A., Stobiecki, M., Jacobs, J., Mete, N., Reshef, A., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2402478 · Cited by 83
Engineering Gene Therapy: Advances and Barriers
Shahryari, A., Burtscher, I., Nazari, Z., & Lickert, H. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100040 · Cited by 87
Antisense Inhibition of Prekallikrein to Control Hereditary Angioedema
Cohn, D. M., Viney, N. J., Fijen, L. M., Schneider, E., Alexander, V. J., Xia, S., Kaeser, G. E., Nanavati, C., Baker, B. F., Geary, R. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915035 · Cited by 80
Self-citationInhibition of Prekallikrein for Hereditary Angioedema
Fijen, L. M., Riedl, M. A., Bordone, L., Bernstein, J. A., Raasch, J. P., Tachdjian, R., Craig, T., Lumry, W. R., Manning, M., Alexander, V. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2109329 · Cited by 75
Self-citationASGR1 and its enigmatic relative, CLEC10A
Hoober, J. K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144818 · Cited by 74
Overcoming the challenges of tissue delivery for oligonucleotide therapeutics
Gökirmak, T., Nikan, M., Wiechmann, S., Prakash, T. P., Tanowitz, M., & Seth, P. P. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.04.010 · Cited by 73
Mondala, P. K., Vora, A. A., Zhou, T., Lazzari, E., Ladel, L., Luo, X., Kim, Y., Costello, C. L., MacLeod, A. R., Jamieson, C. H. M., et al. (2021) · Cell stem cell · doi:10.1016/j.stem.2020.12.017 · Cited by 70
Precision RNA base editing with engineered and endogenous effectors
Pfeiffer, L. S., & Stafforst, T. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01927-0 · Cited by 68
Hepatocyte targeting via the asialoglycoprotein receptor
Ramírez-Cortés, F., & Ménová, P. (2025) · RSC Medicinal Chemistry · doi:10.1039/d4md00652f · Cited by 55
Coelho, T., Ando, Y., Benson, M. D., Berk, J. L., Waddington‐Cruz, M., Dyck, P. J. B., Gillmore, J. D., Khella, S. L., Litchy, W. J., Obici, L. P., et al. (2021) · Neurology and Therapy · doi:10.1007/s40120-021-00235-6 · Cited by 56
Self-citationA call to arms against ultra-rare diseases
Crooke, S. T. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-00945-0 · Cited by 55
Self-citationTherapeutic Antisense Oligonucleotides in Oncology: From Bench to Bedside
Çakan, E., Lara, O. D., Szymanowska, A., Bayraktar, E., Chávez‐Reyes, A., Lopez‐Berestein, G., Amero, P., & Rodriguez‐Aguayo, C. (2024) · Cancers · doi:10.3390/cancers16172940 · Cited by 57
Anand, P., Zhang, Y., Patil, S., & Kaur, K. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02528 · Cited by 56
Palmitic acid conjugation enhances potency of tricyclo-DNA splice switching oligonucleotides
Relizani, K., Echevarría, L., Zarrouki, F., Gastaldi, C., Dambrune, C., Aupy, P., Haeberli, A., Komisarski, M., Tensorer, T., Larcher, T., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab1199 · Cited by 49
Hypertriglyceridemia: new approaches in management and treatment
Wolska, A. T., Yang, Z., & Remaley, A. T. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000710 · Cited by 53
Specificity of oligonucleotide gene therapy (OGT) agents
Nedorezova, D. D., Dubovichenko, M. V., Belyaeva, E. P., Grigorieva, E. D., Peresadina, A. V., & Kolpashchikov, D. M. (2022) · Theranostics · doi:10.7150/thno.77830 · Cited by 50
Directing the Way—Receptor and Chemical Targeting Strategies for Nucleic Acid Delivery
Steffens, R. C., & Wagner, E. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03385-w · Cited by 48
Casu, C., Pettinato, M., Liu, A., Aghajan, M., Presti, V. L., Lidonnici, M. R., Munoz, K. A., O’Hara, E., Olivari, V., Modica, S. M. D., et al. (2020) · Blood · doi:10.1182/blood.2019004719 · Cited by 43
Shirai, T., Revenko, A. S., Tibbitts, J. F., Ngo, A. T. P., Mitrugno, A., Healy, L. D., Johnson, J. S., Tucker, E. I., Hinds, M. T., Coussens, L. M., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000250 · Cited by 44
Antisense oligonucleotide based therapeutics and its applications against bacterial infections
Angrish, N., & Khare, G. (2023) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2023.100166 · Cited by 43
Efficacy and safety of pelacarsen in lowering Lp(a) in healthy Japanese subjects
Karwatowska‐Prokopczuk, E., Lesogor, A., Yan, J., Hurh, E., Hoenlinger, A., Margolskee, A., Xia, S., & Tsimikas, S. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.12.001 · Cited by 39
Self-citationTissue pharmacokinetics of antisense oligonucleotides
Bäckström, E., Bonetti, A., Johnsson, P., Öhlin, S., Dahlén, A., Andersson, P. U., Andersson, S., & Gennemark, P. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102133 · Cited by 40
Loomba, R. S., Morgan, E., Yousefi, K., Li, D., Geary, R. S., Bhanot, S., & Alkhouri, N. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00979-1 · Cited by 39
Self-citationDohrn, M. F., Ihne-Schubert, S. M., Hegenbart, U., Medina, J., Zuchner, S. L., Coelho, T., & Hahn, K. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15233 · Cited by 39
Itakura, S., Shohji, A., Amagai, S., Kitamura, M., Takayama, K., Sugibayashi, K., & Todo, H. (2023) · Scientific Reports · doi:10.1038/s41598-023-30180-3 · Cited by 40
Advances in the genetics of nonalcoholic fatty liver disease
Ajmera, V. H., & Loomba, R. S. (2023) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000927 · Cited by 36
IONIS-PKK Rx a Novel Antisense Inhibitor of Prekallikrein and Bradykinin Production
Ferrone, J. D., Bhattacharjee, G., Revenko, A. S., Zanardi, T. A., Warren, M. S., Derosier, F. J., Viney, N. J., Pham, N. C., Kaeser, G. E., Baker, B. F., et al. (2019) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0754 · Cited by 39
Self-citationLim, K. R. Q., Bittel, A. J., Maruyama, R., Echigoya, Y., Nguyen, Q., Huang, Y., Dzierlega, K., Zhang, A., Chen, Y., & Yokota, T. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.10.010 · Cited by 34
Tschöpe, C., Elsanhoury, A., & Kristen, A. V. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134785 · Cited by 38
Finicle, B. T., Eckenstein, K. H., Revenko, A. S., Anderson, B. A., Wan, W. B., McCracken, A. N., Gil, D., Fruman, D. A., Hanessian, S., Seth, P. P., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad023 · Cited by 30
Foss‐Freitas, M. C., Akıncı, B., Neidert, A., Bartlett, V. J., Hurh, E., Karwatowska‐Prokopczuk, E., & Oral, E. A. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01589-4 · Cited by 31
The promising novel therapies for familial hypercholesterolemia
Chen, R., Lin, S., & Chen, X. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24552 · Cited by 30
Biosafety assessment of delivery systems for clinical nucleic acid therapeutics
Li, Z., Zhang, L., Jiang, K., Zhang, Y., Liu, Y., Hu, G., & Song, J. (2022) · Biosafety and Health · doi:10.1016/j.bsheal.2022.03.003 · Cited by 29
Bioanalysis Considerations on the Pharmacokinetic Evaluation of Antisense Therapeutics
Norris, D. A., Post, N. M., Yu, R. Z., Greenlee, S., & Wang, Y. (2019) · Bioanalysis · doi:10.4155/bio-2019-0194 · Cited by 26
Self-citationCrooke, S. T. (2021) · Nucleic Acid Therapeutics · doi:10.1089/nat.2021.0046 · Cited by 26
Self-citationPreclinical Safety Assessment of Therapeutic Oligonucleotides
Andersson, P. U. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2010-6_25 · Cited by 28
Diep, J. K., Yu, R. Z., Viney, N. J., Schneider, E., Guo, S., Henry, S. P., Monia, B. P., Geary, R. S., & Wang, Y. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15468 · Cited by 25
Self-citationMeeting the needs of patients with ultrarare diseases
Crooke, S. T. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.12.002 · Cited by 24
Self-citationNew Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3
Kim, J. Y., & Kim, N. H. (2023) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2023.12.1.23 · Cited by 23
Ye, D., Cruz‐López, E. O., Tu, H.-C., Zlatev, I., & Danser, A. H. J. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319897 · Cited by 25
Clinical Progress in Hepatic Targeting for Novel Prophylactic Therapies in Hereditary Angioedema
Riedl, M. A., Bordone, L., Revenko, A. S., Newman, K. B., & Cohn, D. M. (2023) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2023.12.025 · Cited by 22
The Progress and Evolving Trends in Nucleic-Acid-Based Therapies
Liu, Y., Wang, C., Fu, X., & Ren, M. (2025) · Biomolecules · doi:10.3390/biom15030376 · Cited by 24
Future directions for medicinal chemistry in the field of oligonucleotide therapeutics
Hall, J. (2023) · RNA · doi:10.1261/rna.079511.122 · Cited by 21
Transport Oligonucleotides—A Novel System for Intracellular Delivery of Antisense Therapeutics
Markov, O. V., Filatov, A. V., Kupryushkin, M. S., Chernikov, I. V., Patutina, O., Strunov, A. A., Chernolovskaya, E. L., Vlassov, V. V., Pyshnyi, D. V., & Аркадьевна, З. М. (2020) · Molecules · doi:10.3390/molecules25163663 · Cited by 20
Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA
Brinton, E. A., Eckel, R. H., Gaudet, D., Ballantyne, C. M., Baker, B. F., Ginsberg, H. N., & Witztum, J. L. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119114 · Cited by 21
Self-citationAntisense oligonucleotide is a promising intervention for liver diseases
Lu, K., Fan, Q., & Zou, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1061842 · Cited by 20
Karwatowska‐Prokopczuk, E., Lesogor, A., Yan, J., Hoenlinger, A., Margolskee, A., Li, L., & Tsimikas, S. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02297-5 · Cited by 19
Self-citationHan, K., Theodore, D., McMullen, G., Swayze, E. E., McCaleb, M. L., Billioud, G., Wieland, S. F., Hood, S. R., Paff, M. T., Bennett, C. F., et al. (2022) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1154 · Cited by 17
Jiang, R., Hooshfar, S., Eno, M. R., Yun, C., Zimmermann, E. S., & Shinkyo, R. (2023) · Current Drug Metabolism · doi:10.2174/1389200224666230418092626 · Cited by 17
Varini, K., Lécorché, P., Sonnette, R., Gassiot, F., Broc, B., Godard, M., David, M., Faucon, A., Abouzid, K., Ferracci, G., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.10.033 · Cited by 19
Nanavati, C., McMullen, G., Yu, R. Z., Geary, R. S., Henry, S. P., & Wang, Y. (2021) · Nucleic Acid Therapeutics · doi:10.1089/nat.2020.0911 · Cited by 15
Self-citationBaker, B. F., Xia, S., Partridge, W., Kwoh, T. J., Tsimikas, S., Bhanot, S., & Geary, R. S. (2022) · Nucleic Acid Therapeutics · doi:10.1089/nat.2022.0044 · Cited by 14
Self-citationInteraction of ASOs with PC4 Is Highly Influenced by the Cellular Environment and ASO Chemistry
Vickers, T. A., Migawa, M. T., Seth, P. P., & Crooke, S. T. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c01808 · Cited by 14
Self-citationSyed, Y. Y. (2025) · Drugs · doi:10.1007/s40265-025-02257-y · Cited by 13
Fukuhara, K., Furihata, K., Matsuoka, N., Itamura, R., Ramos, V. F. M. L., Hagi, T., Kalluru, H., Bramson, C., Terra, S. G., & Liu, J. (2023) · Clinical and Translational Science · doi:10.1111/cts.13498 · Cited by 12
Role of platelet count in a murine stasis model of deep vein thrombosis
Mathews, R., Setthavongsack, N., Le-Cook, A., Kaempf, A. J., Loftis, J. M., Woltjer, R. L., Lorentz, C. U., Revenko, A. S., Hinds, M. T., & Nguyen, K. P. (2023) · Platelets · doi:10.1080/09537104.2023.2290916 · Cited by 12
Zanardi, T. A., Korbmacher, B., Boone, L. I., Engelhardt, J. A., Wang, Y., Burel, S. A., Prill, B., Aghajan, M., Guo, S., & Henry, S. P. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000222 · Cited by 11
Self-citationChunta, S., Khongwichit, S., Swangphon, P., Srisuk, M., Lieberzeit, P. A., & Amatatongchai, M. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c07018 · Cited by 10
Partridge, W., Xia, S., Kwoh, T. J., Bhanot, S., Geary, R. S., & Baker, B. F. (2021) · Nucleic Acid Therapeutics · doi:10.1089/nat.2020.0917 · Cited by 10
Self-citationHereditary Angioedema: Novel Molecules for Treatment of Acute Attacks and Long-Term Prophylaxis
Covella, B., Giliberti, M., Montinaro, A., Rossi, L., & Montinaro, V. (2024) · Future Pharmacology · doi:10.3390/futurepharmacol4010005 · Cited by 9
Progress in molecular biology and translational science addressing the needs of nano-rare patients
Crooke, S. T. (2022) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2022.04.002 · Cited by 8
Self-citationDiscovery of long-acting APOC3 siRNA for treating patients with hypertriglyceridemia
Prakash, T. P., Mullick, A. E., Riney, S., Yu, J., Nikan, M., Quirk, C., Crutchfield, A., Damle, S. S., Klein, S., & Swayze, E. E. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf1063 · Cited by 8
Ito, K., Tajima, G., Kamisato, C., Tsumura, M., Iwamoto, M., Sekiguchi, Y., Numata, Y., Watanabe, K., Yabe, Y., Kanki, S., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci163464 · Cited by 9
Crooke, S. T., Cole, T. A., Carroll, J. B., Gleeson, J. G., Mignon, L., Douville, J., Chung, W. K., Bain, J., Berry‐Kravis, E., Leung, N., et al. (2024) · medRxiv · doi:10.1101/2024.08.05.24310862 · Cited by 8
Self-citationWang, Y., Diep, J. K., Yu, R. Z., Hurh, E., Karwatowska‐Prokopczuk, E., Schneider, E., Henry, S. P., Bhanot, S., & Geary, R. S. (2022) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2121 · Cited by 7
Self-citationAddressing the needs of nano-rare patients: the n-Lorem experience
Crooke, S. T., Glass, S., Gleeson, J. G., Mignon, L., Skourti-Stathaki, K., Douville, J., Knutsen, M., Pu, H., Bain, J., Berry‐Kravis, E., et al. (2026) · Nucleic Acids Research · doi:10.1093/nar/gkag504 · Cited by 7
Self-citationBaker, B. F., Xia, S., Partridge, W., Engelhardt, J. A., Tsimikas, S., Crooke, S. T., Bhanot, S., & Geary, R. S. (2024) · Nucleic Acid Therapeutics · doi:10.1089/nat.2023.0026 · Cited by 8
Self-citationAntisense-Therapie neurologischer Erkrankungen
Pulst, S. (2019) · Der Nervenarzt · doi:10.1007/s00115-019-0724-4 · Cited by 9
Hereditary angioedema: current therapeutic management and future approaches
Lamacchia, D., Nappi, E., Marzio, V., Locatelli, F., Messina, M., & Heffler, E. M. (2024) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000992 · Cited by 7
McGowan, A., Gennemark, P., Akieh‐Pirkanniemi, M., Wirman, L., Davies, N. M., Elebring, M., Tivesten, A., Strimfors, M., Hölttä, M., Söderberg, M. P., et al. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00663 · Cited by 5
Masri, A., Cappelli, F., Davis, M. K., Fontana, M., García‐Pavía, P., Gillmore, J. D., Hanna, M. A., Obici, L. P., Solomon, S. D., Sperry, B. W., et al. (2026) · Circulation Heart Failure · doi:10.1161/circheartfailure.126.014205 · Cited by 6
Self-citationTrivalent siRNA-Conjugates with Guanosine as ASGPR-Binder Show Potent Knock-Down In Vivo
Hofmeister, A., Jahn‐Hofmann, K., Brunner, B., Helms, M. W., Metz-Weidmann, C., Pöverlein, C., Zech, G., Li, Z., Heßler, G., Schreuder, H., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02275 · Cited by 5
Han, K., Ito, H., Elston, R., Cremer, J., Hood, S. R., Paff, M. T., & Theodore, D. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00900-22 · Cited by 5
Emerging Futuristic Targeted Therapeutics
Mistry, T., Nath, A., Pal, R., Ghosh, S., Mahata, S., Sahoo, P. K., Sarkar, S., Choudhury, T., Nath, P., Alam, N., et al. (2023) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000001071 · Cited by 5
Trends and Commonalities of Approved and Late Clinical-Phase RNA Therapeutics
Tufeu, M., Herkenne, C., & Kalia, Y. N. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17070903 · Cited by 4
Delivery science: Its increasing importance for the next generation of medicines
Ashford, M. B., & Bak, A. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114663 · Cited by 5
Fontana, M., Ambardekar, A. V., Cappelli, F., Cuddy, S. A. M., Davis, M. K., García‐Pavía, P., Hanna, M. A., Khouri, M. G., Masri, A., Maurer, M. S., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag168 · Cited by 4
Self-citation
Metadata
- Authors
- Crooke, S. T., Baker, B. F., Xia, S., Yu, R. Z., Viney, N. J., Wang, Y., Tsimikas, S., & Geary, R. S.
- Affiliations
- Ionis Pharmaceuticals (United States) (US)
- Corresponding author
- Crooke, Stanley T.
- ORCID
- Venue
- Nucleic Acid Therapeutics
- Publisher
- SAGE Publications
- Published
- 2019-02-01
- Volume
- 29
- Issue
- 1
- Pages
- 16-32
- ISSN
- 2159-3337 (ISSN-L)
- 2159-3345
- PMC
- PMC6386089
- OpenAlex
- W2906651560
- Cited by
- 127
- References
- 39
- Citations by year
- 2026: 14 · 2025: 18 · 2024: 12 · 2023: 17 · 2022: 17 · 2021: 20 · 2020: 21 · 2019: 8
- FWCI
- 4.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Nucleic Acid Therapeutics (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
- Funders
- Ionis Pharmaceuticals
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- phosphorothioate modification, ASGR1, pharmacokinetics, pharmacodynamics, safety profile, dose-ranging, healthy volunteers, RNA-targeted therapeutics
- MeSH terms
- Acetylgalactosamine, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, RNA, Structure-Activity Relationship, Oligonucleotides, Antisense, Hepatocytes, Asialoglycoprotein Receptor, Biomarkers, Pharmacological, Phosphorothioate Oligonucleotides, Healthy Volunteers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
